Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001178913-18-000468 0001321178 XXXXXXXX LIVE 7 Ordinary Shares, par value NIS 1.0 per share 03/25/2026 false 0001684693 M8694L137 Sol-Gel Technologies Ltd 7 Golda Meir St. Weizmann Science Park Ness Tziona L3 7403648 Perry Wildes, Adv. 972-3-607-4444 One Azrieli Center Tel Aviv L3 6701101 0001321178 Moshe Arkin b PF L3 143257 1806856 143257 1806856 1950113 N 56.6 IN Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026. Y M. Arkin Dermatology Ltd. b WC L3 1806856 1806856 1806856 N 52.44 CO Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 3,245,270 Ordinary Shares outstanding on March 25, 2026, as provided in the Issuer's 424(b)(3) prospectus filed with the Securities and Exchange Commission ("SEC") on March 24, 2026. Ordinary Shares, par value NIS 1.0 per share Sol-Gel Technologies Ltd 7 Golda Meir St. Weizmann Science Park Ness Tziona L3 7403648 This amendment to Schedule 13D is being filed solely to update the percentage holdings of the Reporting Persons following the closing of the Issuer's underwritten offering that closed on March 25, 2026. Item 5 of Schedule 13D is hereby amended and restated as follows: (a) and (b) As of March 25, 2026, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares. Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. As of March 25, 2026, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 143,257 Ordinary Shares, which represented beneficial ownership of approximately 4.41% of the Company's outstanding Ordinary Shares. Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 1,806,856 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 52.44% of the Company's outstanding Ordinary Shares. Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. The total Ordinary Shares beneficially owned by Mr. Arkin as of March 25, 2026, is 1,950,112, which represented beneficial ownership of 56.60% of the Company's outstanding Ordinary Shares. Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares. No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5. Percentages set forth in this amended Schedule 13D were calculated based on 3,245,270 Ordinary Shares outstanding on March 25, 2026 as provided in the Issuer's 424(b)(3) prospectus filed with the SEC on March 24, 2026. Moshe Arkin /s/ Moshe Arkin Moshe Arkin 04/13/2026 M. Arkin Dermatology Ltd. /s/ Moshe Arkin Moshe Arkin, Director 04/13/2026